12 completed, 11 not yet recruiting, 7 unknown, 6 recruiting. 17 Phase 2, 9 Phase 1, 6 Phase 3, 4 Not applicable, 3 Phase 4.
Follow ivarmacitinib: new trials by email Literature Review of ivarmacitinib trials Research Report on ivarmacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivarmacitinib With or Without Celecoxib for Ankylosing Spondylitis Ivarmacitinib with celecoxib, Ivarmacitinib Monotherapy - Ankylosing Spondylitis (AS) | Phase 4 | Not yet recruiting | Peking University Third Hospital | 138 | 2026-10-25 | 2026-10-26 |
| Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets - Systemic Lupus Erthematosus | Phase 2 / Phase 3 | Not yet recruiting | Chinese SLE Treatment And Research Group | 294 | 2026-10-15 | 2026-09-11 |
| JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D Ivarmacitinib, Placebo - T1DM - Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | Huijie Zhang | 132 | 2026-09-30 | 2026-09-29 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors Low-dose ATG + PTCy + Ivarmacitinib - Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 82 | 2026-05-01 | 2026-05-06 |
| Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment, A Phase II Study Ivarmacitinib + Camrelizumab + Fruquintinib - Refractory Metastatic Colorectal Cancer | Phase 2 | Recruiting | Renmin Hospital of Wuhan University | 33 | 2026-04-14 | 2026-10-26 |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis Vanakizumab, Ivarmacitinib, Prednisone - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 180 | 2026-04-01 | 2026-03-05 |
| Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study Ivarmacitinib Sulfate Tablets - Atopic Dermatitis (AD) | Not applicable | Not yet recruiting | Peking University People's Hospital | 300 | 2026-03-31 | 2026-04-24 |
| Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis Ivarmacitinib - Rheumatoid Arthritis | Phase 4 | Not yet recruiting | Tongji Hospital | 100 | 2026-03-01 | 2026-03-05 |
| A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation Ivarmacitinib - aGVHD | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-02-14 | 2026-02-02 |
| Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica Ivarmacitinib tablet, placebo for lvarmacitinib - Polymyalgia Rheumatics (PMR) | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 80 | 2026-01-20 | 2025-12-05 |
| Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance Ivarmacitinib - Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 72 | 2025-12-10 | 2025-12-31 |
| A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo SHR0302 Tablets, SHR0302 Base Gel, SHR0302 Placebo Tablets - Non-segmental Vitiligo | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 176 | 2025-12-05 | 2026-02-18 |
| Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults Ivarmacitinib Sulfate Tablets - Atopic Dermatitis (AD) | Not applicable | Not yet recruiting | Xiangya Hospital of Central South University | 1000 | 2025-11-30 | 2025-12-11 |
| A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis Ivarmacitinib - Palmoplantar Pustulosis (PPP) | Not applicable | Recruiting | Xijing Hospital | 60 | 2025-10-01 | 2025-12-08 |
| JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin - Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 40 | 2024-12-01 | 2024-12-12 |
| Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma SHR-0302, SHR-2554 - Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Recruiting | Fudan University | 25 | 2024-08-12 | 2026-03-24 |
| Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma SHR0302 - Peripheral T Cell Lymphoma | Phase 1 | Unknown | Henan Cancer Hospital | 30 | 2023-05-30 | 2023-06-12 |
| To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability SHR0302 - Graft-versus-host Disease | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2023-05-29 | 2023-12-08 |
Showing 20 of 37. Sign in to see all of them.
Arthritis, Rheumatoid (7) · Dermatitis, Atopic (3) · Alopecia Areata (2) · Colitis, Ulcerative (2) · Graft vs Host Disease (2) · Lymphoma, T-Cell, Peripheral (2) · Spondylitis, Ankylosing (2) · Behcet Syndrome (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Colorectal Neoplasms (1) · Crohn Disease (1) · Diabetes Mellitus, Type 1 (1) · Esophageal Squamous Cell Carcinoma (1) · Non-Radiographic Axial Spondyloarthritis (1)
Jiangsu HengRui Medicine Co., Ltd. (12) · Reistone Biopharma Company Limited (6) · Chinese SLE Treatment And Research Group (2) · Fudan University (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Fujian Cancer Hospital (1) · Henan Cancer Hospital (1) · Huijie Zhang (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Liu Tian (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Renmin Hospital of Wuhan University (1) · Tongji Hospital (1)
China (30) · United States (4) · Poland (3) · Ukraine (3) · Australia (1) · Georgia (1) · Puerto Rico (1)
Xiang Chen (3) · Chen Yu, BS (1) · Huijie Zhang (1) · Jianan Wang (1) · Pei Hu, PhD (1) · Rong Tao, MD (1) · Xianmin Song, M.D. (1) · Xianmin Song, PhD (1) · Xiaofeng Zeng (1) · Xiaofeng Zeng, MD (1)
PMID 34374027, PMID 35963369, PMID 37464978, PMID 38798038, PMID 39919893, PMID 40976531, PMID 41357869, PMID 42466005
2018 (1)